![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhObCLuwmPif4ADQipoc-16Yg22COxGikEkegWdViTIt9A9fB1Ttamh-wJyfMCRF0IcoBF4w8Q62Did8TDMHwdUnhzgZgl2CMY2dauGux5VyK2RQHVzw7yrmzk-96vL8mDFF3i-xb8UyYAZ/s320/PRTO2020051820200605-758961.png)
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in two Phase III clinical trials in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis; has completed a Phase I/II clinical trials for the treatment of patients undergoing arteriovenous graft placement; and has completed Phase I clinical trial for the treatment of symptomatic peripheral artery diseases. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.
http://www.priceseries.com/trade/PRTO-Proteon-Therapeutics-Inc-stock-gains-95-percent-a-Trade-Record-by-priceSeries-2020051820200605.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments